Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Helix to develop insulin skin patch for diabetics :

This article was originally published in Clinica

Executive Summary

Canada's Helix BioPharma is hoping to develop an insulin-delivering skin patch following success with the product in preclinical trials. Animal studies have shown that its Biphasix skin patch was able to deliver insulin in sustained quantities. Blood glucose levels were significantly reduced and remained reduced for more than 30 hours in diabetic rats treated with porcine insulin using the patch, said Helix of Aurora, Ontario. The company plans to develop human insulin formulations on a patch to reduce the need for injections.

You may also be interested in...



EU Preserves Status Quo On Drugs Under Additional Monitoring

The European Commission has set aside, for now, concerns expressed by member states regarding the scope of medicines subjected to additional monitoring requirements.

Meitheal Gets US Enoxaparin Approval

Through its partnership with majority stakeholder Nanjing King-Friend Biochemical Pharmaceutical, Meitheal Pharmaceuticals has received FDA approval for enoxaparin, a generic rival to Lovenox.

EU Approvals: Evenity Cleared For Severe Osteoporosis

The European Commission has granted a marketing authorization for UCB and Amgen’s bone-building MAb, romosozumab, and first launches are expected in the first half of 2020; patient groups suggest that the prevention and treatment of fragility fractures has not attracted the attention it deserves.

 

Topics

UsernamePublicRestriction

Register

MT078127

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel